~(99m)Tc EDDA/HYNIC-TOC: A SUITABLE RADIOPHARMACEUTICAL FOR RADIOGUIDED SURGERY OF NEUROENDOCRINE

摘要

Commercially available ~(111)In-DTPA-octreotide is a well-established radiopharmaceutical for imaging of neuroendocrine tumours (NET) expressing somatostatine receptors. Its analogue [Tyr~3] octreotide can also be successfully radiolabelled with ~(99m)Tc. Compared with mIn labelled preparation, the advantages of ~(99m)Tc labelled [Tyr~3] octreotide are: energy of gamma rays more suitable for registration using gamma detectors and shorter half life, allowing use of higher activities and lower tracer uptake by the kidneys. Its pharmacokinetic properties do not differ significantly from commercially available ~(111)In-DTPA-octreotide [1]. For reasons stated above, the authors propose ~(99m)Tc labelled [Tyr~3] octreotide for radioguided surgery of NET using a gamma probe.